Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
February 08, 2023 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch – –...
February 01, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
January 05, 2023 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma - - Employee headcount reduced...
January 04, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
November 22, 2022 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
November 11, 2022 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy - - iPSC-derived CAR gamma delta T cells shown...
November 10, 2022 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently - - Ended third quarter 2022 with cash, cash equivalents, and...
November 02, 2022 07:05 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

PHILADELPHIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
October 05, 2022 16:05 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the SITC 37th Annual Meeting

PHILADELPHIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...